search
Back to results

Tranexamic Acid in Chinese Elderly Patients With Intertrochanteric Fracture RCT

Primary Purpose

Fracture of Femur

Status
Unknown status
Phase
Phase 4
Locations
Hong Kong
Study Type
Interventional
Intervention
Tranexamic Acid
Sponsored by
The University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fracture of Femur focused on measuring elderly, intertrochanteric fracture

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults over the age of 60
  • Acute isolated intertrochanteric fracture and sub trochanteric fracture treated with short proximal femoral nailing

Exclusion Criteria:

  • Use of any anticoagulant at the time of admission
  • Documented allergy to tranexamic acid
  • History of pulmonary embolism or deep vein thrombosis
  • Hepatic failure
  • Severe renal insufficiency
  • Active coronary artery disease in the past 12 months
  • History of cerebrovascular accident in the past 12 months
  • Presence of a drug-eluting stent
  • Active oncological diseases
  • Coagulopathy (international normalised ratio (INR)>1.4)
  • Pathological fractures
  • Periprosthetic fractures
  • Operation >2 days from admission

Sites / Locations

  • Queen Mary Hospital, The University of Hong Kong

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Local administration of tranexamic acid

Control group

Arm Description

All patients hip fracture will be treated according to the hospital standard procedure Check complete blood count on admission and Day 3 post-operation. 10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop. Transfusion when clinically indicated or Hb < 8g/dL Blood Loss calculation (formula of Nadler, Hidalgo and Bloch) Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable. After discharge, patients will be seen in 6 weeks and 3 months

All patients hip fracture will be treated according to the hospital standard procedure Check complete blood count on admission and Day 3 post-operation. 10ml normal saline injected under the deep fascia around the fracture site under x-ray control Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop. Transfusion when clinically indicated or Hb < 8g/dL Blood Loss calculation (formula of Nadler, Hidalgo and Bloch) Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable. After discharge, patients will be seen in 6 weeks and 3 months

Outcomes

Primary Outcome Measures

Transfusion rate
The total blood transfusion post operation
Blood loss
Blood loss calculation according to formula of Nadler, Hidalgo and Bloch

Secondary Outcome Measures

3 months mortality rate
mortality rate of the patient within post operation 3 months
Complications
Complications related to thrombotic events

Full Information

First Posted
February 27, 2020
Last Updated
March 17, 2020
Sponsor
The University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT04290884
Brief Title
Tranexamic Acid in Chinese Elderly Patients With Intertrochanteric Fracture RCT
Official Title
The Use of Tranexamic Acid in Chinese Elderly Patients Undergoing Femoral Nailing for Intertrochanteric Fracture: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 23, 2018 (Actual)
Primary Completion Date
February 14, 2020 (Actual)
Study Completion Date
May 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Hip fracture posed a major challenge to the health care system, with the one-year mortality of hip fracture reported as being approximately 20%. Perioperative haemoglobin level was associated with functional level of the patient and even mortality. Different methods for administration of tranexamic acid had been described. It was well established that systemic administration of tranexamic acid could reduce perioperative blood loss and transfusion rate. Topical administration had been shown to decrease blood loss and transfusion rate. The objective of our study is to investigate the hypothesis that tranexamic acid will reduce blood loss and transfusion rate in elderly patients undergoing hip fracture surgery.
Detailed Description
The incidence of geriatric hip fractures is projected to increase by more than 250% in the next twenty-five years as the world population ages. Hip fracture in elderly patients are associated with significant morbidity and mortality. One of the significant morbidity is blood loss, which has been reported as high as 1500ml. Blood loss may lead subsequent blood transfusion. The rate of blood transfusion has been reported between 20 to 60%. Blood loss and subsequent blood transfusion could lengthen the overall hospital length of stay and delay the rehabilitation. Tranexamic acid, one of antifibrinolytic agents, is a synthetic derivative of the amino acid lysine and acts as a competitive inhibitor in the activation of plasminogen to plasmin, therefore preventing the degradation of fibrin. Shakur et al. reported that the use could reduce mortality in trauma patients. Tranexamic acid has been widely used in elective orthopaedic surgery such as total joint replacement and spine surgery. Several authors reported that tranexamic acid could decreases the blood loss, transfusion rate and cost.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fracture of Femur
Keywords
elderly, intertrochanteric fracture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Local administration of tranexamic acid
Arm Type
Experimental
Arm Description
All patients hip fracture will be treated according to the hospital standard procedure Check complete blood count on admission and Day 3 post-operation. 10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop. Transfusion when clinically indicated or Hb < 8g/dL Blood Loss calculation (formula of Nadler, Hidalgo and Bloch) Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable. After discharge, patients will be seen in 6 weeks and 3 months
Arm Title
Control group
Arm Type
No Intervention
Arm Description
All patients hip fracture will be treated according to the hospital standard procedure Check complete blood count on admission and Day 3 post-operation. 10ml normal saline injected under the deep fascia around the fracture site under x-ray control Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop. Transfusion when clinically indicated or Hb < 8g/dL Blood Loss calculation (formula of Nadler, Hidalgo and Bloch) Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable. After discharge, patients will be seen in 6 weeks and 3 months
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Other Intervention Name(s)
Transamin
Intervention Description
The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
Primary Outcome Measure Information:
Title
Transfusion rate
Description
The total blood transfusion post operation
Time Frame
Day 3 post operation
Title
Blood loss
Description
Blood loss calculation according to formula of Nadler, Hidalgo and Bloch
Time Frame
Day 3 post operation
Secondary Outcome Measure Information:
Title
3 months mortality rate
Description
mortality rate of the patient within post operation 3 months
Time Frame
from post operation to 3 months
Title
Complications
Description
Complications related to thrombotic events
Time Frame
from post operation to 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults over the age of 60 Acute isolated intertrochanteric fracture and sub trochanteric fracture treated with short proximal femoral nailing Exclusion Criteria: Use of any anticoagulant at the time of admission Documented allergy to tranexamic acid History of pulmonary embolism or deep vein thrombosis Hepatic failure Severe renal insufficiency Active coronary artery disease in the past 12 months History of cerebrovascular accident in the past 12 months Presence of a drug-eluting stent Active oncological diseases Coagulopathy (international normalised ratio (INR)>1.4) Pathological fractures Periprosthetic fractures Operation >2 days from admission
Facility Information:
Facility Name
Queen Mary Hospital, The University of Hong Kong
City
Hong Kong
Country
Hong Kong

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
2109105
Citation
Schneider EL, Guralnik JM. The aging of America. Impact on health care costs. JAMA. 1990 May 2;263(17):2335-40.
Results Reference
background
PubMed Identifier
20850741
Citation
Bhaskar D, Parker MJ. Haematological indices as surrogate markers of factors affecting mortality after hip fracture. Injury. 2011 Feb;42(2):178-82. doi: 10.1016/j.injury.2010.07.501.
Results Reference
background
PubMed Identifier
18349013
Citation
Foss NB, Kristensen MT, Kehlet H. Anaemia impedes functional mobility after hip fracture surgery. Age Ageing. 2008 Mar;37(2):173-8. doi: 10.1093/ageing/afm161.
Results Reference
background
PubMed Identifier
14641869
Citation
Lawrence VA, Silverstein JH, Cornell JE, Pederson T, Noveck H, Carson JL. Higher Hb level is associated with better early functional recovery after hip fracture repair. Transfusion. 2003 Dec;43(12):1717-22. doi: 10.1046/j.0041-1132.2003.00581.x.
Results Reference
background
PubMed Identifier
28538384
Citation
Zhang P, He J, Fang Y, Chen P, Liang Y, Wang J. Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis. Medicine (Baltimore). 2017 May;96(21):e6940. doi: 10.1097/MD.0000000000006940.
Results Reference
background
PubMed Identifier
26978136
Citation
Drakos A, Raoulis V, Karatzios K, Doxariotis N, Kontogeorgakos V, Malizos K, Varitimidis SE. Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery. J Orthop Trauma. 2016 Aug;30(8):409-14. doi: 10.1097/BOT.0000000000000577.
Results Reference
background
PubMed Identifier
27235515
Citation
Tengberg PT, Foss NB, Palm H, Kallemose T, Troelsen A. Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial. Bone Joint J. 2016 Jun;98-B(6):747-53. doi: 10.1302/0301-620X.98B6.36645. Erratum In: Bone Joint J. 2016 Dec;98-B(12 ):1711-1712.
Results Reference
background

Learn more about this trial

Tranexamic Acid in Chinese Elderly Patients With Intertrochanteric Fracture RCT

We'll reach out to this number within 24 hrs